Evidence map›Paper›PMID 39428566›Full record

ArticleCNS neuroscience & therapeutics2024

Exploratory Analysis of the Association Between Plasma Ceramide Alterations and Cognitive Dysfunction in Parkinson's Disease.

Xu Liu, Xuanjing Liu, Yuning Liu, Bo Yang, Yangdanyu Li, Fujia Li, Kun Qian, Xuesong Liu, Lishun Xiao, Guiyun Cui and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xu LiuDepartment of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Xuanjing LiuDepartment of Neurology, the First Clinical College, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Yuning LiuDepartment of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Bo YangDepartment of Neurology, the First Clinical College, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Yangdanyu LiDepartment of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Fujia LiDepartment of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Kun QianDepartment of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Xuesong LiuDepartment of Neurology, the First Clinical College, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Lishun XiaoDepartment of Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Guiyun CuiDepartment of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Chuanying XuDepartment of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.ORCID 0009-0006-0851-9298

Funding

Jiangsu Postgraduate Research and Practice Innovation Program KYCX23_2977Leadership program through open competition in Xuzhou Medical University JBGS202203Medical Science and Technology Innovation Project of Xuzhou Health Commission XWKYHT20220158National Natural Science Foundation of China 82401683The China Postdoctoral Science Foundation 2020M671607The National Natural Science Foundation of China 12001470
6 · The paper itself

Abstract

objectivePrior research has underscored the importance of sphingolipid metabolism in Parkinson's disease (PD) pathogenesis. Our objective was to explore the associations between plasma ceramide levels and PD patients with cognitive dysfunction (PD-CD).

methodsWe enrolled two study populations from Eastern China and the Parkinson's Progression Markers Initiative (PPMI), comprising 290 (100 HCs, 160 PDs, and 30 MSAs) and 429 (125 HCs and 304 PDs) participants, respectively. The plasma levels of ceramides (Cer 16:0, Cer 18:0, Cer 24:0, and Cer 24:1) were tested via HPLC-MS/MS analysis.

resultsCompared with those in the HC group, the plasma levels of Cer 18:0, Cer 24:1, Cer 16:0/Cer 24:0, Cer 18:0/Cer 24:0, and Cer 24:1/Cer 24:0 were higher in both the PD and MSA groups. Significant differences in the plasma levels of Cer 16:0/Cer 24:0, Cer 18:0/Cer 24:0, and Cer 24:1/Cer 24:0 were observed among the PD-NC (PD with normal cognition), PD-MCI (PD with mild cognitive impairment), and PDD (PD dementia) groups, with the PDD group exhibiting the highest levels. PD patients with higher baseline levels of plasma ceramides (specifically, Cer 18:0, Cer 16:0/Cer 24:0, Cer 18:0/Cer 24:0, and Cer 24:1/Cer 24:0) demonstrated accelerated cognitive decline compared with individuals who had lower baseline plasma ceramide levels during the 5-year follow-up period. A biomarker panel including Cer 18:0/Cer 24:0 and Cer 24:1/Cer 24:0 could effectively differentiate PD-CD from PD-NC with notable diagnostic accuracy.

conclusionsOur results indicate that plasma ceramide levels could potentially be used as diagnostic biomarkers for PD-CD.

Indexed as

CeramidesCognitive DysfunctionParkinson DiseaseAgedBiomarkersFemaleHumansMaleMiddle AgedBiomarkersCeramidesbiomarkerceramidecognitive dysfunctionParkinson's disease

Identifiers

PMID39428566
PMCPMC11491299

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.